Afamelanotide

阿法诺肽

Report date: 2025/01/14 16:41:53
NMEFirst In Class

Base Information

Drug NameAfamelanotide
Drug Alias Name阿美兰肽Melanotan I[Nle4,DPhe7]-alpha-MSHAfamelanotidumAfamelanotida +[13] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionMelanocortin receptor agonists
TargetsMelanocortin receptor
Therapy Area/IndicationsRejection of organ transplantationIschemic StrokeUrticaria +[10] 
Global Approved IndicationsProtoporphyria, Erythropoietic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2014/12/22
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesThe University Of Arizona
China Registration ClassN/A

Develop Information

Active CompaniesClinuvel Europe LtdClinuvel Pharmaceuticals LtdClinuvel Inc
Inactive CompaniesN/A
Active IndicationsIschemic StrokeVitiligoProtoporphyria, Erythropoietic +[5] 
Inactive IndicationsRejection of organ transplantationUrticariaAcne Vulgaris +[5] 

Other Information

ATC CodeD02BB02
Related LinksWikipediaDrugBankKEGG